Implantable cardioverter defibrillators: Uses, abuses, gains and complications

Sudden cardiac death (SCD) due to a ventricular arrhythmia is one of the most common causes of death, yet its management continues to be a challenge. Controlled clinical trials have provided evidence that implantable cardioverter defibrillators (ICDs) are effective in reducing the risk of SCD in sel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weiwei Li, Brian Olshansky
Formato:	article
Lenguaje:	EN
Publicado:	South African Heart Association 2017
Materias:	sudden cardiac death implantable cardioverter defibrillators Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/8498874455444f71ac23c801a0f43ca4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8498874455444f71ac23c801a0f43ca4
record_format	dspace
spelling	oai:doaj.org-article:8498874455444f71ac23c801a0f43ca42021-11-26T13:13:33ZImplantable cardioverter defibrillators: Uses, abuses, gains and complications10.24170/7-3-19441996-67412071-4602https://doaj.org/article/8498874455444f71ac23c801a0f43ca42017-04-01T00:00:00Zhttps://www.journals.ac.za/index.php/SAHJ/article/view/1944https://doaj.org/toc/1996-6741https://doaj.org/toc/2071-4602Sudden cardiac death (SCD) due to a ventricular arrhythmia is one of the most common causes of death, yet its management continues to be a challenge. Controlled clinical trials have provided evidence that implantable cardioverter defibrillators (ICDs) are effective in reducing the risk of SCD in selected patients with ischaemic or non-ischaemic cardiomyopathy and/or ventricular arrhythmias. As increasing numbers of patients become eligible for ICDs, deciding whom should receive these becomes more complex, especially in patients with borderline risk factors and those with co-morbidities in whom the risk of death from nonarrhythmic cardiovascular cause is higher. What type of ICD a patient should receive remains a challenge. While ICD shocks themselves can affect outcomes adversely, no other therapy has proven more effective to date. Risks of implantation include infection, lead dislodgement and perforation. An ongoing challenge which also needs to be addressed includes whom will be footing the bill for device implants. More data is required to determine which patient population will benefit the most from ICD implants.Weiwei LiBrian OlshanskySouth African Heart Associationarticlesudden cardiac deathimplantable cardioverter defibrillatorsDiseases of the circulatory (Cardiovascular) systemRC666-701ENSA Heart Journal, Vol 7, Iss 3, Pp 154-164 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	sudden cardiac death implantable cardioverter defibrillators Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	sudden cardiac death implantable cardioverter defibrillators Diseases of the circulatory (Cardiovascular) system RC666-701 Weiwei Li Brian Olshansky Implantable cardioverter defibrillators: Uses, abuses, gains and complications
description	Sudden cardiac death (SCD) due to a ventricular arrhythmia is one of the most common causes of death, yet its management continues to be a challenge. Controlled clinical trials have provided evidence that implantable cardioverter defibrillators (ICDs) are effective in reducing the risk of SCD in selected patients with ischaemic or non-ischaemic cardiomyopathy and/or ventricular arrhythmias. As increasing numbers of patients become eligible for ICDs, deciding whom should receive these becomes more complex, especially in patients with borderline risk factors and those with co-morbidities in whom the risk of death from nonarrhythmic cardiovascular cause is higher. What type of ICD a patient should receive remains a challenge. While ICD shocks themselves can affect outcomes adversely, no other therapy has proven more effective to date. Risks of implantation include infection, lead dislodgement and perforation. An ongoing challenge which also needs to be addressed includes whom will be footing the bill for device implants. More data is required to determine which patient population will benefit the most from ICD implants.
format	article
author	Weiwei Li Brian Olshansky
author_facet	Weiwei Li Brian Olshansky
author_sort	Weiwei Li
title	Implantable cardioverter defibrillators: Uses, abuses, gains and complications
title_short	Implantable cardioverter defibrillators: Uses, abuses, gains and complications
title_full	Implantable cardioverter defibrillators: Uses, abuses, gains and complications
title_fullStr	Implantable cardioverter defibrillators: Uses, abuses, gains and complications
title_full_unstemmed	Implantable cardioverter defibrillators: Uses, abuses, gains and complications
title_sort	implantable cardioverter defibrillators: uses, abuses, gains and complications
publisher	South African Heart Association
publishDate	2017
url	https://doaj.org/article/8498874455444f71ac23c801a0f43ca4
work_keys_str_mv	AT weiweili implantablecardioverterdefibrillatorsusesabusesgainsandcomplications AT brianolshansky implantablecardioverterdefibrillatorsusesabusesgainsandcomplications
_version_	1718409301951774720

Implantable cardioverter defibrillators: Uses, abuses, gains and complications

Ejemplares similares